Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GPP-Baladol

            Therapeutic Area: Infections and Infectious Diseases Product Name: PNB-001

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 27, 2020

            Details:

            The effect of PNB 001 (GPP-Baladol) will be compared with dexamethasone, currently the most used medication for COVID-19 treatment. The molecule has already been patented and the related IPRs have been secured by PNB VESPER in the US, Europe and rest of the world.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BBV152

            Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 23, 2020

            Details:

            The latest development is supported by assessment of safety and immunogenicity data of Phase I and II clinical trials of Covaxin. Covaxin has been derived from a strain of SARS-CoV-2 virus and uses adjuvant Alhydroxiquim-II to boost immune response.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NVX-COV2373,Matrix-M

            Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Novavax

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement September 15, 2020

            Details:

            Under the erms of the amended deal, SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two billion doses annually.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): BBV152

            Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin

            Highest Development Status: Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            The phase 2 human clinical trial of Bharat Biotech's coronavirus vaccine Covaxin at PGI Rohtak will involve 300 volunteers.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Aqueous extract of Cocculus Hirsutus

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 05, 2020

            Details:

            First phytopharmaceutical drug approved for clinical trial by DCGI for COVID-19 Clinical trial will be conducted across 12 centers in India in 210 patients. Drug has shown anti-SARS-CoV-2 effects in in-vitro studies conducted in collaboration with ICGEB, Italy.